Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Researchers explore benefits and risks of biosimilar antibodies

Researchers explore benefits and risks of biosimilar antibodies

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Variations in ERAP1 enzyme could lead to Ankylosing Spondylitis

Variations in ERAP1 enzyme could lead to Ankylosing Spondylitis

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis